Eve & Co (TSXV:EVE) announced Health Canada authorized its subsidiary Natural MedCo to use a previously constructed flowering room as a grow area and a packaging room as an operations area.

As quoted in the press release:


With the addition of these approved areas, Eve & Co now has 220,000 [square feet] of licensed grow and operation areas. The Company expects harvesting to commence at its newly licensed second flowering room by late March 2019.

Natural MedCo Ltd. has also received authorization to commence sales of additional types of cannabis products, including fresh and dried cannabis, to provincially authorized retailers and distributors. Eve & Co is now authorized to sell a variety of cannabis products to provincially authorized retailers and distributors, including fresh and dried cannabis and cannabis plants, and to other licensed cultivators and processors on the B2B market, including fresh and dried cannabis, cannabis plants and cannabis oil.

“The addition of Flowering Room #2 will allow us to more than double our current production levels and to grow in our new, state of the art flowering room. Approval for Packaging Room #2 will allow us to start using our automated packaging line to efficiently and quickly fill orders in immediate packaging. The amendment to our sales license expands our market to not only other licensed producers but also to provincial distributors,” commented Melinda Rombouts, Eve & Co’s President and CEO.

Click here to read the full press release.

Source: globenewswire.com

 Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Aurora securities between February 13, 2020, and September 4, 2020, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/acb .

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

Keep reading... Show less

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Aurora Cannabis Inc. (NYSE: ACB) from February 13, 2020 through September 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aurora Cannabis Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

Keep reading... Show less

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less